Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

ABSTRACT:

Background

The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tumor DNA (ctDNA) to predict and monitor relapse in resected stage III melanoma.

Patients and methods

Somatic mutations were identified in 99/133 (74%) patients through tumor tissue sequencing. Personalized droplet digital PCR (ddPCR) assays were used to detect known mutations in 315 prospectively collected plasma samples from mutation-positive patients. External validation was performed in a prospective independent cohort (n = 29).

Results

ctDNA was detected in 37 of 99 (37%) individuals. In 81 patients who did not receive a

SUBMITTER: Tan L 

PROVIDER: S-EPMC6551451 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature